<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font20 { font-size : 20; } .font21 { font-size : 21; } .font24 { font-size : 24; } .font25 { font-size : 25; } .font29 { font-size : 29; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">HIV- </span>
   <span class="font29">cluster </span>
   <span class="font25">resistance </span>
   <span class="font24">viral </span>
   <span class="font21">large </span>
   <span class="font20">drug </span>
   <span class="font20">dolutegravir </span>
   <span class="font18">integrase </span>
   <span class="font17">mutations </span>
   <span class="font16">HIV </span>
   <span class="font16">viruses </span>
   <span class="font16">(n = ) </span>
   <span class="font15">:–. </span>
   <span class="font15">clusters </span>
   <span class="font15">antiretroviral </span>
   <span class="font15">strains </span>
   <span class="font14">singleton/small </span>
   <span class="font14">variants </span>
   <span class="font14">concentrations </span>
   <span class="font14">{border-style </span>
   <span class="font14">week </span>
   <span class="font14">(cluster </span>
   <span class="font14">elvitegravir </span>
   <span class="font14">px;} </span>
   <span class="font13">#ffffff;} </span>
   <span class="font13">MSM </span>
   <span class="font13">acquisition </span>
   <span class="font13">based </span>
   <span class="font13">isolates </span>
   <span class="font13">lineages </span>
   <span class="font13">selections </span>
   <span class="font13">size </span>
   <span class="font13">IV, </span>
   <span class="font13">culture </span>
   <span class="font13">small </span>
   <span class="font13">VI, </span>
   <span class="font13">compared </span>
   <span class="font13">lamivudine </span>
   <span class="font13">presence </span>
   <span class="font13">replicative </span>
   <span class="font13">selected </span>
   <span class="font12">development </span>
   <span class="font12">performed </span>
   <span class="font12">pressure </span>
   <span class="font12">selection </span>
   <span class="font12">treatment </span>
   <span class="font12">(–) </span>
   <span class="font12">associated </span>
   <span class="font12">fitness </span>
   <span class="font12">infection </span>
   <span class="font12">transmission </span>
   <span class="font12">using </span>
   <span class="font12">Infect </span>
   <span class="font12">analysis </span>
   <span class="font12">appearance </span>
   <span class="font12">sequencing </span>
   <span class="font12">vitro </span>
   <span class="font12">AIDS;: </span>
   <span class="font12">RK, </span>
   <span class="font12">acquired </span>
   <span class="font12">belonging </span>
   <span class="font12">clinical </span>
   <span class="font12">cohort </span>
   <span class="font12">dolutegravir, </span>
   <span class="font12">epidemic </span>
   <span class="font12">high </span>
   <span class="font12">including </span>
   <span class="font12">patients </span>
   <span class="font12">ED, </span>
   <span class="font12">LI, </span>
   <span class="font12">activity </span>
   <span class="font12">deep </span>
   <span class="font12">escape </span>
   <span class="font12">isolate </span>
   <span class="font12">mutation </span>
   <span class="font12">new </span>
   <span class="font12">previously </span>
   <span class="font12">selective </span>
   <span class="font12">showed </span>
   <span class="font12">substitutions </span>
   <span class="font11">Antimicrob </span>
   <span class="font11">SN, </span>
   <span class="font11">TA, </span>
   <span class="font11">Viral </span>
   <span class="font11">dominant </span>
   <span class="font11">increasing </span>
   <span class="font11">leading </span>
   <span class="font11">observed </span>
   <span class="font11">phylogenetic </span>
   <span class="font11">px; </span>
   <span class="font11">quasi-species </span>
   <span class="font11">rapid </span>
   <span class="font11">related </span>
   <span class="font11">replication </span>
   <span class="font11">spread </span>
   <span class="font11">therapy </span>
   <span class="font11">weekly </span>
   <span class="font11">{font-family </span>
   <span class="font11">(%) </span>
   <span class="font11">(.%) </span>
   <span class="font11">Chemother;: </span>
   <span class="font11">Dis; </span>
   <span class="font11">Figure </span>
   <span class="font11">Large </span>
   <span class="font11">Sanger </span>
   <span class="font11">[], </span>
   <span class="font11">dolutegravir  lamivudine </span>
   <span class="font11">emergence </span>
   <span class="font11">font-size </span>
   <span class="font11">frequency </span>
   <span class="font11">individual </span>
   <span class="font11">infected </span>
   <span class="font11">inhibitor </span>
   <span class="font11">men </span>
   <span class="font11">pressure. </span>
   <span class="font11">reported </span>
   <span class="font11">transmitted </span>
   <span class="font11">virus </span>
   <span class="font11">GE, </span>
   <span class="font11">Quebec </span>
   <span class="font11">accumulation </span>
   <span class="font11">cell </span>
   <span class="font11">cultured </span>
   <span class="font11">different </span>
   <span class="font11">double; </span>
   <span class="font11">drugs </span>
   <span class="font11">elvitegravir, </span>
   <span class="font11">failing </span>
   <span class="font11">features </span>
   <span class="font11">first-line </span>
   <span class="font11">following </span>
   <span class="font11">genetic </span>
   <span class="font11">genotypic </span>
   <span class="font11">genotyping </span>
   <span class="font11">higher </span>
   <span class="font11">individuals </span>
   <span class="font11">inhibitors </span>
   <span class="font11">levels </span>
   <span class="font11">newly </span>
   <span class="font11">novel </span>
   <span class="font11">passage </span>
   <span class="font11">raltegravir </span>
   <span class="font11">results </span>
   <span class="font11">reverse </span>
   <span class="font11">subtype </span>
   <span class="font11">weeks </span>
   <span class="font11">(Figurea). </span>
   <span class="font11">AIDS </span>
   <span class="font11">CBMCs </span>
   <span class="font11">Engl </span>
   <span class="font11">Health </span>
   <span class="font11">MI, </span>
   <span class="font11">Med; </span>
   <span class="font11">Montreal </span>
   <span class="font11">PHI </span>
   <span class="font11">RNA </span>
   <span class="font11">Research </span>
   <span class="font11">TI, </span>
   <span class="font11">University </span>
   <span class="font11">absence </span>
   <span class="font11">al.Transmission </span>
   <span class="font11">and/or </span>
   <span class="font11">antiviral </span>
   <span class="font11">barrier </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">cells </span>
   <span class="font11">clustering </span>
   <span class="font11">competence </span>
   <span class="font11">determined </span>
   <span class="font11">dolutegravir. </span>
   <span class="font11">escalations </span>
   <span class="font11">findings </span>
   <span class="font11">followed </span>
   <span class="font11">harbouring </span>
   <span class="font11">increases </span>
   <span class="font11">infections </span>
   <span class="font11">inhibitors. </span>
   <span class="font11">isolated </span>
   <span class="font11">mutations, </span>
   <span class="font11">networks </span>
   <span class="font11">obtained </span>
   <span class="font11">outgrowth </span>
   <span class="font11">patient </span>
   <span class="font11">patterns </span>
   <span class="font11">persons </span>
   <span class="font11">population </span>
   <span class="font11">potential </span>
   <span class="font11">prevent </span>
   <span class="font11">primary </span>
   <span class="font11">rapidly </span>
   <span class="font11">resulted </span>
   <span class="font11">revealed </span>
   <span class="font11">solid; </span>
   <span class="font11">studies </span>
   <span class="font11">time </span>
   <span class="font11">used </span>
   <span class="font11">versus </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">–), </span>
   <span class="font10">(Figure). </span>
   <span class="font10">(Figureb). </span>
   <span class="font10">ART </span>
   <span class="font10">AT, </span>
   <span class="font10">Abstract </span>
   <span class="font10">Acquir </span>
   <span class="font10">Center </span>
   <span class="font10">Defic </span>
   <span class="font10">Dis;: </span>
   <span class="font10">Dolutegravir </span>
   <span class="font10">EQ, </span>
   <span class="font10">Foundation </span>
   <span class="font10">Hospitals </span>
   <span class="font10">Immune </span>
   <span class="font10">Isolate </span>
   <span class="font10">Lancet;: </span>
   <span class="font10">Phylogenetic </span>
   <span class="font10">acid </span>
   <span class="font10">amino </span>
   <span class="font10">assays </span>
   <span class="font10">blood </span>
   <span class="font10">bold </span>
   <span class="font10">combination </span>
   <span class="font10">contributed </span>
   <span class="font10">courier; </span>
   <span class="font10">diagnoses </span>
   <span class="font10">distinct </span>
   <span class="font10">dual </span>
   <span class="font10">early </span>
   <span class="font10">em; </span>
   <span class="font10">entire </span>
   <span class="font10">enzymatic </span>
   <span class="font10">epidemics </span>
   <span class="font10">founder </span>
   <span class="font10">groups </span>
   <span class="font10">however, </span>
   <span class="font10">hypermutation </span>
   <span class="font10">infection: </span>
   <span class="font10">laboratory </span>
   <span class="font10">lineages. </span>
   <span class="font10">lower </span>
   <span class="font10">number </span>
   <span class="font10">pathways </span>
   <span class="font10">periods </span>
   <span class="font10">phase </span>
   <span class="font10">phylogenetics </span>
   <span class="font10">pressure, </span>
   <span class="font10">prevention </span>
   <span class="font10">prophylaxis </span>
   <span class="font10">pt;} </span>
   <span class="font10">rates </span>
   <span class="font10">regimens </span>
   <span class="font10">resistance, </span>
   <span class="font10">resistance. </span>
   <span class="font10">resistant </span>
   <span class="font10">sequencing. </span>
   <span class="font10">sex </span>
   <span class="font10">single </span>
   <span class="font10">strand </span>
   <span class="font10">study </span>
   <span class="font10">supernatant </span>
   <span class="font10">tenofovir </span>
   <span class="font10">transcriptase </span>
   <span class="font10">transfer </span>
   <span class="font10">transmissions </span>
   <span class="font10">treatment-naive </span>
   <span class="font10"> weeks. </span>
  </p>
 </body>
</html>
